Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: a multicenter prospective study in China

Background::Generic drugs are bioequivalent to their brand-name counterparts; however, concerns still exist regarding the effectiveness and safety of generic dr...     

Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China

Background and AimsThe National Centralized Drug Procurement (NCDP) policy was launched in mainland China in April 2019, with entecavir (ETV) and tenofovir disoproxil fumarate (TDF) being included in the procurement list. We conducted the current study to investigate the impact of the NCDP policy on the utilization and expenditures of antiviral therapy for chronic hepatitis B (CHB) in China.MethodsProcurement records, including monthly purchase volume, expenditure, and price of nucleos(t)ide analogs (NAs), were derived from the National Healthcare Security Administration from April 2018 to March 2021. The changes in volumes and expenditures of the first-line NAs and bid-winning products were calculated. The effects of price, volume, and structure related to drug expenditure were calculated by the Addis and Magrini (AM) Index System Analysis.ResultsThe purchase volume of NAs significantly increased from 134.3 to 318.3 million DDDs, whereas the expenditure sharply decreased from 1,623.41 to 490.43 million renminbi (RMB) or 241.94 to 73.09 million US dollars (USD). The proportions of first-line NAs rose from 72.51% (ETV: 69.00%, TDF: 3.51%) to 94.97% (ETV: 77.42%, TDF: 17.55%). AM analysis showed that the NCDP policy decreased the expenditure of all NAs (S=0.91) but increased that of the first-line NAs in the bid-winning list (S=1.13). Assuming the population size of CHB patients remains stable and a compliance rate of ≥75%, the proportion of CHB patients receiving first-line antiviral therapy would increase from 6.36–8.48% to 11.56–15.41%.ConclusionsThe implementation of the NCDP policy significantly increased the utilization of first-line NAs for CHB patients at a lower expenditure. The findings provided evidence for optimizing antiviral therapy strategy and allocating medical resources in China.     

SLC2A3 variants in familial and sporadic congenital heart diseases in a Chinese Yunnan population

BackgroundSolute carrier family 2 member 3 (SLC2A3), is a member of a superfamily of transport protein genes. SLC2A3 played an important role in embryonic development. Previous research reported SLC2A3 duplication was reportedly associated with congenital syndromic heart defects. However, it is not clear whether the gene is associated with non‐syndromic congenital heart disease. Our study aimed to elucidate the relationship between its variation and congenital heart disease.MethodsGenomic DNA extracted from the peripheral blood leukocytes of two families with CHD were sequenced with whole‐exome sequencing to identify variations, used Sanger sequencing to investigate SLC2A3 variants in 494 Chinese patients with CHD and 576 healthy unrelated individuals.ResultsIn members from the two families, three with CHD had the SLC2A3 (rs3931701) C > T variant. Of the 494 patients with CHD, 394 had gene variants (86 had the TT type and 308 had the CT type). Of the 576 healthy controls, 272 participants had gene variants (36 had the TT type and 236 had the CT type). The TT type [p < 0.0001, odds ratio (OR) =7.262, 95% confidence interval (CI) =4.631–11.388] and CT type (p < 0.0001, OR =3.967, 95% CI =2.991–5.263) of SLC2A3 (rs3931701) significantly increased the risk of sporadic ASD in a Chinese Yunnan population.ConclusionsSingle nucleotide variations of SLC2A3, particularly, the SLC2A3 (rs3931701) C > T variant increased the risk of CHD among the studied population.     

Enhanced tumor homing of pathogen-mimicking liposomes driven by R848 stimulation: A new platform for synergistic oncology therapy

Although multifarious tumor-targeting modifications of nanoparticulate systems have been attempted in joint efforts by our predecessors, it remains challenging for nanomedicine to traverse physiological barriers involving blood vessels, tissues, and cell barriers to thereafter demonstrate excellent antitumor effects. To further overcome these inherent obstacles, we designed and prepared mycoplasma membrane (MM)-fused liposomes (LPs) with the goal of employing circulating neutrophils with the advantage of inflammatory cytokine-guided autonomous tumor localization to transport nanoparticles. We also utilized in vivo neutrophil activation induced by the liposomal form of the immune activator resiquimod (LPs-R848). Fused LPs preparations retained mycoplasma pathogen characteristics and achieved rapid recognition and endocytosis by activated neutrophils stimulated by LPs-R848. The enhanced neutrophil infiltration in homing of the inflammatory tumor microenvironment allowed more nanoparticles to be delivered into solid tumors. Facilitated by the formation of neutrophil extracellular traps (NETs), podophyllotoxin (POD)-loaded MM-fused LPs (MM-LPs-POD) were concomitantly released from neutrophils and subsequently engulfed by tumor cells during inflammation. MM-LPs-POD displayed superior suppression efficacy of tumor growth and lung metastasis in a 4T1 breast tumor model. Overall, such a strategy of pathogen-mimicking nanoparticles hijacking neutrophils in situ combined with enhanced neutrophil infiltration indeed elevates the potential of chemotherapeutics for tumor targeting therapy.     

腕管综合征的MRI诊断

研究腕管综合征（CTS）的MRI特征及应用价值。材料和方法：经临床及手术证实的CTS12例，行MRI检查，以横断面为主。结果：12例CTS的MRI表现为：正中神经进入腕管时肿胀增粗12例，正中神经肿胀率（MNSR）为2．25：1。正中神经腕管内受压变扁12冽，正中神经扁平率（MNFR）为3．4。腕横韧带向掌侧膨隆10例，腕横韧带膨隆率（BR）为15．8％。T2WI像正中神经信号增高12例。结论：MRI对CTS的诊断、治疗方式的选择及疗效观察有重要的价值。     

青少年椎间盘钙化自发性恢复1例报告并文献复习

椎间盘钙化是成人常见脊柱疾病,而在青少年中较为罕见[1-2].青少年椎间盘钙化是一种自限性疾病,大多数患者主要表现为颈部、背部和上肢疼痛及斜颈等,也有一些无症状患者在常规体检中被发现,通常预后良好.目前,对于症状性青少年椎间盘钙化是采用非手术治疗还是积极手术治疗仍有争议.有研究[3-5]显示,青少年椎间盘钙化经非手术治疗大多预后良好,少数患者出现复发或进展.因此,有必要通过长期随访研究来明确青少年椎间盘钙化是否需要手术治疗.本研究通过复习相关文献,并结合本院收治的1例青少年椎间盘钙化自发性恢复患者的诊疗过程,探讨青少年椎间盘钙化的可能病因、诊疗方案及其引发的严重神经系统症状的长期预后.     

新生儿缺氧缺血性脑病43例临床与预后分析

分析新生儿缺氧缺血性脑病（ＨＩＥ）４３例。有宫内窘迫史者占５８１％,出生重度窒息占８１４％。ＨＩＥ轻度１０例,中度２６例,重度７例。合并心肌损害达４１７％。治愈好转率为８１３％。病死率７０％。随访２４例,轻度ＨＩＥ预后好,中度有明显后遗症者为６７％,重度预后不良。认为加强围生期保健,提高产科质量,进行新法复苏及复苏后处理是降低ＨＩＥ发病率的关键。诊治中应重视心肌损害。使用胞二磷胆碱等脑细胞代谢激活剂辅治ＨＩＥ效果肯定。对于预后,强调早期治疗,早期评分、早期随访、早期干预是改善重度ＨＩＥ预后的几个重要环节。